Sector Gamma AS Reduces Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Sector Gamma AS lessened its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 11.0% during the 4th quarter, HoldingsChannel reports. The fund owned 102,490 shares of the biopharmaceutical company’s stock after selling 12,676 shares during the quarter. Ultragenyx Pharmaceutical comprises approximately 1.2% of Sector Gamma AS’s portfolio, making the stock its 27th biggest holding. Sector Gamma AS’s holdings in Ultragenyx Pharmaceutical were worth $4,901,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of the business. UMB Bank n.a. boosted its stake in shares of Ultragenyx Pharmaceutical by 118.8% during the 4th quarter. UMB Bank n.a. now owns 606 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 329 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of Ultragenyx Pharmaceutical by 2.2% during the 3rd quarter. Arizona State Retirement System now owns 20,163 shares of the biopharmaceutical company’s stock worth $719,000 after acquiring an additional 441 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 38.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,979 shares of the biopharmaceutical company’s stock worth $95,000 after acquiring an additional 548 shares during the last quarter. Covestor Ltd boosted its stake in shares of Ultragenyx Pharmaceutical by 392.1% during the 3rd quarter. Covestor Ltd now owns 748 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 596 shares during the last quarter. Finally, Xponance Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 6.8% during the 4th quarter. Xponance Inc. now owns 10,162 shares of the biopharmaceutical company’s stock worth $486,000 after acquiring an additional 648 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Up 0.9 %

NASDAQ RARE traded up $0.39 on Friday, reaching $44.24. The company had a trading volume of 450,422 shares, compared to its average volume of 704,581. The stock has a market capitalization of $3.64 billion, a PE ratio of -5.31 and a beta of 0.65. The firm’s 50 day moving average price is $47.80 and its 200 day moving average price is $43.81. Ultragenyx Pharmaceutical Inc. has a 12 month low of $31.52 and a 12 month high of $54.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.13. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative return on equity of 369.54%. The company had revenue of $127.39 million for the quarter, compared to the consensus estimate of $119.38 million. During the same period in the previous year, the firm posted ($2.16) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was up 23.3% compared to the same quarter last year. On average, research analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.38 EPS for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, EVP Thomas Richard Kassberg sold 11,509 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $49.93, for a total value of $574,644.37. Following the sale, the executive vice president now directly owns 252,823 shares in the company, valued at approximately $12,623,452.39. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, EVP Thomas Richard Kassberg sold 11,509 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $49.93, for a total value of $574,644.37. Following the sale, the executive vice president now directly owns 252,823 shares in the company, valued at approximately $12,623,452.39. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Matthew K. Fust sold 12,195 shares of the business’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $50.88, for a total transaction of $620,481.60. Following the completion of the sale, the director now owns 14,860 shares in the company, valued at $756,076.80. The disclosure for this sale can be found here. Insiders have sold a total of 32,116 shares of company stock worth $1,645,983 in the last three months. Insiders own 6.80% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on RARE shares. TD Cowen lifted their price target on shares of Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Wednesday. Robert W. Baird lifted their target price on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an “outperform” rating in a research note on Tuesday, January 30th. JPMorgan Chase & Co. lifted their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, March 18th. Canaccord Genuity Group lifted their target price on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a “buy” rating in a research note on Wednesday, February 21st. Finally, Wedbush restated a “neutral” rating and set a $48.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, April 16th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.08.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.